Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Lucile Vanhersecke
(1, 2)
,
Maxime Brunet
(1, 2)
,
Jean-Philippe Guégan
(3)
,
Christophe Rey
(3)
,
Antoine Bougouin
(4)
,
Sophie Cousin
(1)
,
Sylvestre Le Moulec
(5)
,
Benjamin Besse
(6, 7)
,
Yohann Loriot
(6)
,
Mathieu Larroquette
(1, 2)
,
Isabelle Soubeyran
(1)
,
Maud Toulmonde
(1)
,
Guilhem Roubaud
(1)
,
Simon Pernot
(1)
,
Mathilde Cabart
(1)
,
Francois Chomy
(1)
,
Corentin Lefevre
(1)
,
Kevin Bourcier
(1)
,
Michele Kind
(1)
,
Ilenia Giglioli
(4)
,
Catherine Sautes-Fridman
(4)
,
Valerie Velasco
(1)
,
Felicie Courgeon
(3)
,
Ezoglin Oflazoglu
(8)
,
Ariel Savina
(8)
,
Aurelien Marabelle
(6, 9)
,
Jean-Charles Soria
(6)
,
Carine Bellera
(1, 10)
,
Casimir Sofeu
(1)
,
Alban Bessede
(3)
,
Wolf H. Fridman
(4)
,
Francois Le Loarer
(1, 2)
,
Antoine Italiano
(2, 1, 6)
1
Institut Bergonié [Bordeaux]
2 UB - Université de Bordeaux
3 Explicyte Immuno-Oncology [Bordeaux]
4 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
5 Clinique Marzet [Pau]
6 IGR - Institut Gustave Roussy
7 Département de médecine oncologique [Gustave Roussy]
8 Astra Zeneca [Rahway, New Jersey]
9 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
10 BPH - Bordeaux population health
2 UB - Université de Bordeaux
3 Explicyte Immuno-Oncology [Bordeaux]
4 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
5 Clinique Marzet [Pau]
6 IGR - Institut Gustave Roussy
7 Département de médecine oncologique [Gustave Roussy]
8 Astra Zeneca [Rahway, New Jersey]
9 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
10 BPH - Bordeaux population health
Isabelle Soubeyran
- Fonction : Auteur
- PersonId : 762161
- ORCID : 0000-0001-7501-7622
Carine Bellera
- Fonction : Auteur
- PersonId : 769480
- ORCID : 0000-0001-7926-4671
- IdRef : 203945417
Antoine Italiano
- Fonction : Auteur
- PersonId : 760314
- ORCID : 0000-0002-8540-5351
Résumé
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.